AstraZeneca plc (LON:AZN)‘s stock had its “sell” rating reissued by stock analysts at Goldman Sachs Group Inc. in a research report issued on Thursday. They currently have a GBX 4,000 ($48.75) price objective on the biopharmaceutical company’s stock. Goldman Sachs Group Inc.’s price objective would indicate a potential downside of 13.09% from the stock’s current price.
Several other research analysts have also recently commented on the stock. Bryan, Garnier & Co restated a “buy” rating on shares of AstraZeneca plc in a report on Thursday, July 28th. Morgan Stanley restated an “overweight” rating and set a GBX 5,000 ($60.94) target price on shares of AstraZeneca plc in a report on Monday, July 11th. BNP Paribas set a GBX 5,300 ($64.59) target price on shares of AstraZeneca plc and gave the stock a “buy” rating in a report on Tuesday, August 2nd. Jefferies Group increased their target price on shares of AstraZeneca plc from GBX 4,100 ($49.97) to GBX 4,450 ($54.24) and gave the stock a “hold” rating in a report on Thursday, June 30th. Finally, Deutsche Bank AG restated a “buy” rating and set a GBX 6,200 ($75.56) target price on shares of AstraZeneca plc in a report on Tuesday, October 11th. Five investment analysts have rated the stock with a sell rating, fourteen have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of GBX 4,966.24 ($60.53).
Shares of AstraZeneca plc (LON:AZN) opened at 4602.244 on Thursday. AstraZeneca plc has a 52-week low of GBX 3,680.00 and a 52-week high of GBX 5,505.00. The firm has a 50-day moving average of GBX 4,975.27 and a 200 day moving average of GBX 4,532.38. The firm’s market capitalization is GBX 58.22 billion.